Genialis – a computational precision medicine company that is unraveling complex biology to find new ways to address disease – announced it raised over $13 million in Series A financing to transform the way diseases are diagnosed and treatment decisions are generated. Taiwania Capital and Debiopharm Innovation Fund co-led the funding round participation from previous investors First Star Ventures, Redalpine Venture Partners, and Pikas. And the other new investors include P5 Health Ventures and several Angels. Ita Lu of Taiwania and Hamzeh Abdul-Hadi of Debiopharm are joining Genialis’ Board of Directors.
Genialis is developing advanced patient classifiers using machine learning and high-throughput omics data to capture underlying disease biology and predict how patients are likely going to respond to targeted therapies. And the company plans to use the funds from the Series A funding to expand its proprietary ResponderID platform and build out its comprehensive collection of clinically validated biomarker models to offer pinpoint diagnoses for virtually every cancer patient.
So far, Genialis has used ResponderID in collaboration with biopharma to analyze clinical trial data and inform future trial designs for numerous investigational drugs. And Genialis also supports the commercialization of next-gen biomarker assays with several leading diagnostic firms.
ResponderID is a machine learning platform for clinical and translational research -which was built from years of experience working with several partners across the industry and advanced internal R&D. ResponderID brings new biomarkers for drug development and discovery programs along with diagnostic tests. Plus ResponderID can read the status of virtually any NGS-based biomarker, including bespoke and proprietary signatures, from a single assay. The resulting output offers clinical and translational researchers with a comprehensive molecular portrait of patient disease phenotype enabling the most informed decision-making possible.
Last year, there were 10 publications and poster presentations at major scientific conferences that featured results generated with ResponderID, including AACR, ESMO, and SITC. Genialis also co-authored a paper in the Journal of Clinical Oncology describing OncXerna’s navicixizumab ph1b trial, including retrospective analysis with the Xerna TME Panel.
Now Genialis is growing its teams in the U.S. and Slovenia across the business, operations, life science, and data science functions, and expanding its advisory boards. And the company is also investing in R&D collaborations with several cancer centers, hospital groups, and clinical academic labs.
KEY QUOTES:
“With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery. We chose to focus initially on biomarkers that improve the efficiency of drug development, that ensure the right patient gets the right medicine, and make an impact on real people’s lives in a shorter period of time.”
— Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis
“ResponderID, Genialis’ predictive biomarker platform, enables precision medicine by identifying patients that are most likely to respond to treatments. Its use in drug development will optimize study designs and improve chances of clinical trials success, driving much-needed productivity gains for pharma R&D and accelerating the time to market for promising new drugs.”
— Hamzeh Abdul-Hadi, Investment Director at Debiopharm Innovation Fund
“Genialis is leading the collision of biology and AI. Our approach is biology first, but with a deep commitment to getting the data science right. Thus, we only succeed as a team that understands both worlds. This capital brings together a global syndicate of clinical oncology and deep tech experts and will allow us to grow our in-house capabilities in multiple disciplines.”
— Miha Stajdohar, Ph.D., co-founder and CTO of Genialis
“Genialis has an impressively clear vision, compelling AI-drug discovery biomarker models, and robust underlying science supporting their platform. We look forward to working closely with the Genialis team to explore and pursue growth opportunities in this burgeoning space.”
— Ita Lu, Managing Partner, Taiwania Capital Management
